Mr. Charlie Ban is the Chairman of Epiecho (Beijing) Medical Technology Co. Ltd. and Epi-Shen Medical Biotechnology (GuangDong) Co. Ltd.
Since 2015, Mr. Ban has also been the Managing Director of VisionGain Capital, an asset management company licensed by the Securities and Futures Commission in Hong Kong. With over 20 years of experience in investment banking, wealth management, and private equity, he has worked at various financial institutions in New York, Hong Kong, and Beijing.
Before joining VisionGain, Mr. Ban served as a Venture Partner at SAIF Partners China. He has also worked at esteemed firms such as AIG, Goldman Sachs, Citibank, and HSBC from 1996 to 2011, gaining valuable expertise in the field.
Charlie Ban holds an Executive Master of Business Administration (EMBA) degree from Peking University in China and a Master of Business Administration (MBA) degree from Pace University in the USA. These educational qualifications have further enhanced his knowledge and skills in business and management.
With his extensive background in finance and investment, Mr. Charlie Ban brings a wealth of expertise to his roles as Chairman of Epiecho (Beijing) Medical Technology Co. Ltd. and Epi-Shen Medical Biotechnology (GuangDong) Co. Ltd., as well as his position at VisionGain Capital.